CytomX Therapeutics (NASDAQ: CTMX) reported Q2 EPS of ($0.09), $0.01 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $1.41 million versus the consensus estimate of $11.33 million.

For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.